Skip to main content
Amit Jain, MD, Oncology, Tupelo, MS

Amit Jain MD


Hematology Oncology Fellow

Join to view full profile
  • 961 S Gloster StTupelo, MS 38801

Dr. Jain is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Summary

  • Dr. Amit Jain is an oncologist based in Tupelo, MS. He completed his fellowship in Hematology and Medical Oncology, and his residency in Internal Medicine at the University of Tennessee. Dr. Jain has authored several publications, focusing on topics related to oncology, with his work frequently cited by peers. His recent study on the 27-gene Immuno-Oncology Score and its association with the efficacy of checkpoint immunotherapy in advanced non-small cell lung cancer has been highlighted in notable journals such as Clinical Lung Cancer and BMC Cancer.

Education & Training

  • University of Tennessee College of Medicine
    University of Tennessee College of MedicineFellowship, Hematology and Medical Oncology, 2020 - 2023
  • University of Tennessee College of Medicine (Memphis)
    University of Tennessee College of Medicine (Memphis)Residency, Internal Medicine, 2017 - 2020
  • Other
    OtherClass of 2015

Certifications & Licensure

  • MS State Medical License
    MS State Medical License 2022 - 2027
  • Internal Medicine
    American Board of Internal Medicine Internal Medicine
  • Hematology
    American Board of Internal Medicine Hematology
  • Medical Oncology
    American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

Journal Articles

  • Predictors of Mortality in Metastatic Papillary Renal Cell Cancer  
    • Sidana A, Jain AL (Presenter), Kadakia M, Krane S, Friend J, Muthigi A, Ninos M, Shih J, Srinivasan R., Journal Of Clinical Oncology
  • Outcomes with CDK4/6 inhibitors based on endocrine sensitivity in hormone receptor-positive metastatic breast cancer (HR+ MBC)  
    • Jain AL, Mullins JN, Poorman KA, Chaudhry A, Ranganath HA, Miller EM, Valasareddy P, Smith JR, Ryder J, Winerip M, Schwartzberg LS, Vidal GA, Journal of Clinical Oncology, 2019

Abstracts/Posters

  • Comparison of End-Fire VS. Side-Fire Ultrasound Probes for MRI/TRUS Fusion-Guided Prostate Biopsy.
    Jain AL, Sidana A, Stanik Z, Maruf M, Calio B, Sugano D, Gommella P, Hammerich K, Yan P, Turkbey B, Choyke P, Wood B, Pinto P., Society of Urologic Oncology, San Antonio, 11/2017
  • Urologist's Practice Patterns And Preferences Regarding Focal Therapy For Prostate Cancer.
    • Jain A, Sidana A, Sugano D, Calio B, Maruf M, Choyke P, Turkbey B, Wood BJ, Pinto P, AUA, Boston, 5/2017

Lectures

  • Outcomes with CDK4/6 inhibitors based on endocrine sensitivity in hormone receptor-positive metastatic breast cancer (HR+ MBC). 
    ASCO Annual Meeting 2019 - Chicago, IL - 5/31/2019

Research History

  • Research ScholarNational Cancer Institute, Bethesda, MD2016 - 2017

Professional Memberships

Other Languages

  • Hindi, Tamil

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: